---

Dr. Ewen Cameron is head of platform at Sail Biomedicines and an operating partner at Flagship Pioneering, where he has served to conceive, originate and build platform companies. At Sail, he has responsibility for the continued advancement of the company’s targeted nanoparticle and Endless RNA™ (eRNA™) platforms. Prior to joining Sail, Ewen was co-founder and head of platform at Repertoire Immune Medicines and was on the founding team of Alltrna. He served as co-founder and president of multiple stealth companies, developing platform technologies now integrated into Ampersand Biomedicines and Metaphore Biotechnologies.

Ewen received his PhD in microbiology and molecular genetics from Harvard University and his undergraduate degree from Yale University. He further trained as a research fellow at the Massachusetts Institute of Technology and the Howard Hughes Medical Institute, focusing on synthetic biology.